
WilmerHale Reps Eleven Biotherapeutics in Acquisition of Viventia Bio

SEPTEMBER 22, 2016

Eleven Biotherapeutics, Inc. and Viventia Bio Inc. announced that the two companies and the shareholders of Viventia entered into a definitive share purchase agreement under which Eleven Biotherapeutics agreed to, and simultaneously completed, the acquisition of Viventia.

The acquisition creates a NASDAQ-listed company focused on the development of novel therapies based upon antibody fragments genetically fused to cytotoxic proteins, or targeted protein therapeutics, as new treatments in areas of oncology with significant unmet need.

The WilmerHale representation was led by Partners [Brian Johnson](#) and [Hal Leibowitz](#) (M&A). The Corporate team included Partner [Belinda Juran](#), Counsel [Chris Barnstable-Brown](#), Senior Associate [Ryan Mitteness](#), and Associates [Claire Sarno](#), [Colin Beauvais](#) and [John Wagner](#). Tax, Executive Compensation and Employee Benefits advice was provided by Partners [Bill Caporizzo](#), [Amy Null](#), [Laura Schneider](#) and [Kimberly Wethly](#), and Counsel [Meghan Walsh](#).

Read the [press release](#) for more information.